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Abstract 
The purpose of this study was to evaluate
predictors of appropriate therapy in patients
with  implantable  cardioverter-defibrillators
(ICD) for primary prevention of sudden car-
diac  death.  A  retrospective  cohort  of  321
patients with systolic heart failure undergoing
ICD placement for primary prevention of sud-
den cardiac death was queried with a mean
follow-up period of 2.6 years. Appropriate ICD
therapy was defined as therapy delivered for
termination of a ventricular tachyarrhythmia.
Appropriate ICD therapy was delivered in 142
(44%) of the patients. In a multivariate model,
body mass index ≥28.8 kg/m
2 , chronic kidney
disease, left ventricular ejection fraction ≤20%
and  metabolic  syndrome  were  found  to  be
independent  predictors  of  appropriate  ICD
therapy. Appropriate ICD therapy was associat-
ed with higher cardiovascular mortality. These
findings show the importance of identification
of risk factors, especially metabolic syndrome,
in  patients  following  ICD  implantation  as
aggressive treatment of these co-morbidities
may  decrease  appropriate  ICD  therapy  and
cardiovascular mortality.
Introduction
Several  randomized  controlled  trials  have
demonstrated  a  survival  benefit  with  an
implantable  cardioverter-defibrillator  (ICD)
among patients who are at high risk for sud-
den cardiac death in primary prevention set-
tings.
1-4 It is of major importance to identify
patients who will benefit from ICD implanta-
tion and generator replacement after battery
depletion.  From  multivariate  risk  profiles,
approximately 50-60% of patients will receive
an  ICD  therapy  within  9±11  months  after
implantation,  including  an  average  of  2.3
shocks/patient/year.
5-8 ICD  therapy  decreases
quality of life and increases health care uti-
lization.
9 Therefore it is important for clini-
cians to identify the predictors of ICD therapy
in  order  to  prevent  ICD  shocks  which  may
improve quality of life and reduce healthcare
costs.  Although  randomized  studies  provide
the best evidence, longitudinal studies provide
complementary data. The purpose of this study
was to identify predictors for appropriate ICD
therapy using demographic and clinical char-
acteristics in patients who have received ICD
for  primary  prevention  of  sudden  cardiac
death.
As  there  is  little  information  available
regarding the impact of metabolic syndrome
(MetS) on sudden death in a heart failure pop-
ulation, we also sought to determine if individ-
ual components of metabolic syndrome itself
are associated with appropriate ICD therapy. 
Materials and Methods
A retrospective cohort of 321 patients with
systolic  heart  failure  undergoing  ICD  place-
ment for primary prevention of sudden cardiac
death  was  queried  from  April  2004  to
September 2008, at the Regions Hospital of
University  of  Minnesota  Medical  School.  All
patients  had  ICD  placement  based  on  the
American  Heart  Association  recommenda-
tions for primary prevention of sudden cardiac
death.  All  patients  received  standard  heart
failure  treatment  including  beta-blocker,
angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers, lipid-lowering
drugs, aspirin and diuretics based on the dis-
cretion of the treating physician.
Clinical data collected at the time of ICD
placement included: age, gender, smoking his-
tory, hypertension, hypercholesterolemia, and
diabetes  mellitus.  Fasting  lipid  profile  was
assessed for all patients as was information on
statin use. Left ventricular function was deter-
mined by transthoracic echocardiogram prior
to the implantation. The clinical identification
of patients with MetS was based on the modi-
fied  criteria  proposed  by  the  National
Cholesterol  Education  Program-Adult  Treat  -
ment Panel III (NCEP-ATPIII).
10 Patients were
considered to have MetS when 3 of the 5 fol-
lowing  criteria  were  present:  i)  body  mass
index (BMI) ≥28.8 kg/m
2;
11,12 ii) elevated fast-
ing glucose ≥110 mg/dL or drug treatment for
elevated blood sugar; iii) fasting triglycerides
≥150 mg/dL; iv) reduced high-density lipopro-
tein cholesterol <40 mg/dL for men and <50
mg/dL for women; v) blood pressure ≥130/85
mmHg or drug treatment for elevated blood
pressure. BMI was used instead of waist cir-
cumference as waist circumference was not
routinely documented in the medical record.
MetS status was evaluated at the time of ICD
placement.
Chronic kidney disease (CKD) was defined
according to the National Kidney Foundation
Classification based on glomerular filtration
rate (GFR): stage 1 (normal GFR ≥90 mL/min
per 1.73 m
2) and persistent albuminuria; stage
2 (GFR 60 to 89 mL/min per 1.73 m
2) and per-
sistent  albuminuria;  stage  3  (GFR  30  to  59
mL/min per 1.73 m
2); stage 4 (GFR 15 to 29
mL/min per 1.73 m
2); and stage 5 (GFR<15
mL/min per 1.73 m
2).
13 The GFR was estimated
using  the  Modification  of  Diet  in  Renal
Disease (MDRD) study equation.
13
Follow-up
The mean follow-up period was 2.6 years.
Follow-up consisted of reviewing the clinical
visits,  emergency  department  visits,  urgent
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care  visits  and  hospital  records.  Outcomes
measured were appropriate ICD therapy and
cardiovascular mortality. Among patients who
had more than one ICD therapy, only one was
recorded for analysis. Stored data were ana-
lyzed to classify the arrhythmias responsible
for precipitating ICD therapy according to the
following definitions.
14 Ventricular fibrillation
or  flutter  was  defined  as  ventricular  tach-
yarrhythmias with a cycle length of 240 ms or
less.  Ventricular  tachycardia  was  defined  as
ventricular  tachyarrhythmias  with  a  cycle
length of more than 240 ms.
An appropriate ICD therapy was defined as
antitachycardia pacing for termination of ven-
tricular tachycardia and/or ICD shock for ter-
mination of ventricular tachycardia or ventric-
ular fibrillation.
Cardiovascular  death  included  all  patients
who died of cardiovascular causes (myocardial
infarction,  heart  failure  and  cerebrovascular
accidents) as determined by review of medical
records and the social security death index.
Statistical analysis
All  statistical  analyses  were  performed
using STATA 10.0 software (StataCorp, Texas,
USA). Continuous variables were expressed as
mean ± standard deviation and were compared
by using 2-sample t tests for independent sam-
ples. Differences in proportion were compared
using c
2 test or Fisher’s exact test, as appropri-
ate. Univariate analysis was carried out with
Cox’s regression and hazards ratio (HR) was
calculated.  Multivariate  analysis  was  per-
formed with logistic regression to assess the
factors independently associated with adverse
outcomes. A probability value P≤0.05 was con-
sidered statistically significant.
Results
A total of 321 patients with systolic heart
failure  (mean  age  72±11  years,  65%  male)
underwent ICD placement for primary preven-
tion of sudden cardiac death. Of 321 patients,
90% had ischemic cardiomyopathy. The aver-
age ejection fraction was 26.5±11.3%. Thirty-
nine percent of patients had diabetes mellitus,
69% had hypertension, and 29% had chronic
kidney disease. 
Forty-one percent of the patients were iden-
tified  as  having  MetS.  The  average  age  of
patients with MetS was 70±8 years and 71±6
years for those without MetS (P>0.05). Ninety-
one percent of patients with MetS and 89% of
patients  with  non-MetS  had  ischemic  car-
diomyopathy (P>0.05). Baseline characteristic
are shown in Table 1. Both groups had a high-
er  prevalence  of  male  patients  (P=ns).  The
mean  ejection  fraction  was  23.4±7.4%  with
MetS and 28.9±9.3% without MetS (P=0.04).
The  prevalence  of  diabetes  (49%  vs. 32%,
P=0.01) and chronic kidney disease (23% vs.
14%, P=0.002) were higher in patients with
MetS as compared to those without MetS.
Appropriate  ICD  therapy  was  delivered  in
142 (44%) patients. Of those, 46 (14%) experi-
enced shocks and 96 (30%) had antitachycar-
dia pacing with no shocks.
Cox’s regression analysis was performed to
obtain unadjusted hazards ratio (HR) for fol-
lowing variables to identify the predictors of
appropriate ICD therapy: age >70 years, body
mass  index  ≥28.8  Kg/m
2,  New  York  Heart
Association heart failure class ≥ III, diabetes
mellitus,  HDL  <40,  left  ventricular  ejection
fraction  ≤20%,  and  chronic  kidney  disease.
Table 1.  Baseline patient’s characteristics. 
All MetS Non-MetS P
(321) (n=131) (n=190) ns
Age (years) 72±11 70±8 71±6
Male (%) 65 66 64 ns
Ejection fraction (%) 26.5±11.3 23.4±7.4 28.9±9.3 0.04
BMI ≥28.8 kg/m
2 (%) 56 73 44 0.001
Ischemic cardiomyopathy (%) 90 91 89 ns
NYHA heart failure class (%)
II 16 15 17 ns
III 73 77 70 0.04
IV 11 10 12 ns
DM-2 (%) 39 49 32 0.01
HTN (%) 69 76 64 0.03
CKD (%) 18 23 14 0.002
COPD (%) 24 22 25 ns
Fasting glucose (mg/dL) 142±39 172±29 121±21 0.02
HDL (mg/dL) 39±10 32±7 44±7 0.001
Triglycerides(mg/dL) 144±27 169±21 125±11 0.01
Systolic blood pressure (mmHg) 132±31 149±24 127±21 0.03
Diastolic blood pressure (mmHg) 89±19 93±17 86.5±9 0.07
QRS duration (ms) 121.2±26.8 119±18.7 122.1±24.9 ns
Medications (%)
Aspirin 81 83 79 ns
Beta blocker 88 91 87 ns
ACEI 71 64 75 0.04
ARB 21 28 16 0.02
Diuretics 28 39 21 0.01
Statin 61 62 60 ns
ACEI: angiotensin converting enzymes inhibitors; ARB: angiotensin receptor blockers; BMI: body mass index; COPD: chronic obstructive pul-
monary disease; DM: diabetes mellitus; HTN: hypertension; HDL: high density lipoprotein; MS: millisecond; NYHA: New York Heart Association;
ns: not significant (P>0.05).
Table 2. Univariate predictor of appropriate ICD therapy. 
Hazard ratio P
Age >70 years 1.29 (1.09-1.71) 0.02
Male 0.92 (0.61-1.42) 0.62
Diabetes mellitus 2.13 (1.21-3.43) 0.01
HTN 1.87 (0.56-1.87) 0.54
LVEF ≤20% 4.66 (2.31-9.34) <0.001
NYHA heart failure class ≥ III 1.41 (1.11-3.01) 0.04
Fasting blood sugar ≥110 mg/dL 0.93(0.46-1.64) 0.08
HDL <40 2.03(1.32-3.42) 0.002
TG ≥150 1.82(1.63-2.51) 0.04
BMI ≥28.8 kg/m
2 2.56 (1.26-5.85) 0.001
CKD 2.06(1.34-4.36) 0.003
COPD 0.91(0.41-1.98) 0.76
Beta blocker therapy 1.21(0.85-2.46) 0.23
BMI: body mass index; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; HDL: high density lipoprotein; HTN:
hypertension; TG: triglycerides.Article
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Table 2 shows the predictors of appropriate ICD
therapy  by  Cox’s  regression  analysis.  After
including  these  variables  in  a  multivariate
model, body mass index ≥28.8 kg/m
2 (adjusted
HR=1.96, 95% CI 1.12-2.91, P=0.01), left ven-
tricular ejection fraction ≤ 20% (adjusted HR
3.95, 95% CI 2.69-8.11, P<0.001) and chronic
kidney disease (adjusted HR 1.28, 95% CI 1.09-
2.13,  P=0.02)  were  found  to  be  independent
predictors of appropriate ICD therapy. In the
subgroup of patients who had ICD shocks for
ventricular fibrillation (VF), body mass index
≥28.8 kg/m
2 and left ventricular ejection frac-
tion ≤20% were found to be predictors of VF in
both univariate and multivariate analyses, left
ventricular ejection fraction ≤20% was found to
be the only predictor for ventricular fibrillation
(adjusted HR 2.7, 95% CI 1.37-5.31, P=0.004).
QRS duration was not a predictor of appropri-
ate ICD therapy in our study population.
Although all components of MetS other than
body mass index ≥28.8 kg/m
2 were not inde-
pendent predictors of appropriate ICD therapy,
further multivariate analysis was carried out to
evaluate whether MetS itself was an independ-
ent predictor of appropriate ICD therapy (Table
3). In the multivariate analysis, after adjusting
for age, sex, medications, left ventricular ejec-
tion  fraction  and  co-morbidities,  MetS  was
found to be a significant predictor of appropri-
ate ICD therapy (OR 2.01, 95% CI, 1.12-3.88,
P=0.03). 
During  our  follow-up  period,  29  (9%)
patients died of cardiovascular causes includ-
ing  19  (6%)  patients  who  had  undergone
appropriate ICD therapy and 10 (3%) patients
who had had no ICD therapy. 
In multivariate analysis, after adjusting for
age, sex, medications and comorbidities, left
ventricular ejection fraction ≤20% was associ-
ated with an increased hazard risk cardiovas-
cular mortality (adjusted HR 2.66, 95% CI 1.56-
6.07,  P=0.001).  In  Kaplan-Meier  analysis,
patients  who  had  appropriate  ICD  therapy
were found to have a higher incidence of car-
diovascular mortality (HR= 2.26, 95% CI 1.08-
4.67, P=0.03) than patients without any ICD
therapy (Figure 1).
Discussion 
In the present study, we examined predictors
of appropriate ICD therapy in 321 patients who
received ICD for primary prevention of sudden
cardiac death. We identified body mass index
≥28.8 kg/m
2, left ventricular ejection fraction
≤20% and chronic kidney disease as the inde-
pendent predictors of appropriate ICD therapy.
MetS was also found to be independently asso-
ciated with a higher incidence of appropriate
ICD therapy. We did not find an independent
association between all individual components
of MetS with appropriate ICD therapy in multi-
variate  analysis.  The  results  suggest  that
patients with MetS are at an increased risk of
ventricular  arrhythmia  and  appropriate  ICD
therapy to patients without MetS. 
There is substantial evidence that MetS con-
tributes to the development of heart failure,
but no data exists on the impact of MetS in
patients with heart failure who have received
an ICD. In the present study, we examined the
prevalence and outcomes of the MetS in the
heart failure population who received ICD for
primary prevention of sudden cardiac death.
The  prevalence  of  MetS  was  41%,  which
exceeds that reported in the general popula-
tion, but is lower than reported in heart failure
populations.
15,16 The prevalence of MetS in our
study is lower than two previous studies. The
prevalence of MetS in a heart failure popula-
tion has been reported to be 68.3% and 78% in
prior studies.
16,17 In our study, we found that
patients who had at least one episode of appro-
priate ICD therapy are at higher risk of subse-
quent  cardiovascular  mortality  than  those
without any ICD therapy. This indicates that
patients  who  are  at  higher  risk  for  having
appropriate ICD therapy are also at higher risk
for cardiovascular mortality. This finding is in
accordance with the findings of previous stud-
ies where cardiovascular mortality was found
to be higher with MetS.
18-21 In a meta-analysis
of 21 prospective cohort studies, patients with
MetS  had  increased  cardiovascular  mortality
with relative risk of 1.74 (95% CI 1.29-2.35).
22
Another  meta-analysis  including  37  studies
and 172,573 individuals showed that MetS was
associated with a relative risk of 1.78 for car-
diovascular events and death (95% CI, 1.58-
2.0).
23 MetS has also been found to be associat-
ed with an increased risk of stroke (RR 1.76;
95% CI 1.37-2.25).
22 Appropriate ICD discharge
was found to be higher in MetS, which sug-
gests that patients with MetS are at higher risk
for  arrhythmic  events  and  sudden  cardiac
death.  These  findings  provide  new  evidence
that MetS is associated with an increased risk
of cardiovascular events.
23
Our data suggests that patients with chron-
ic kidney disease are more prone to develop
ventricular arrythmias and receive appropriate
ICD therapy. In a historic cohort study, patients
with chronic kidney disease  were more likely
to  have  experienced  an  acute  myocardial
infarction, angina, heart failure, stroke, and/or
cardiovascular  death  versus  those  with  pre-
served kidney function. In multivariate analy-
sis, chronic kidney disease  was the most sig-
nificant independent risk factor for a cardio-
vascular  event  (HR  2.5,  CI  95%  1.3-4.8).
24
These patients might benefit more from the
ICD placement for primary prevention of sud-
den cardiac death than patients with normal
kidney function. The increased frequency of
ventricular arrhythmias and appropriate ICD
therapy in patients with chronic kidney dis-
ease documented in our study is in keeping
with other reports in the literature.
25,26
Left ventricular ejection fraction was a sig-
nificant risk factor for both appropriate ICD
therapy, ventricular fibrillation and cardiovas-
cular mortality. This finding was in accordance
with previous findings in clinical trials where
left ventricular ejection fraction over 20% was
found to reduce sudden cardiac death risk.
27 In
our study, we did not find an association of
Table  3.  Multivariate  logistic  regression  analysis  showing  independent  predictors  of
implantable cardioverter-defibrillators therapy. 
Predictor HR (95% CI) P
LVEF ≤20% 3.95 (2.69-8.11) <0.001
BMI ≥28.8 kg/m
2  1.96 (1.12-2.91) 0.01
CKD 1.28 (1.09-2.13)  0.02
MetS 2.01 ( 1.12-3.88) 0.03
BMI: body mass index; CI: confidence interval; HR: hazard ratio; MetS: metabolic syndrome.
Figure 1. Kaplan-Meier graph of cardiovas-
cular  mortality  in  patients  with
implantable  cardioverter-defibrillators
therapy  as  compared  to  patients  without
any implantable cardioverter-defibrillators
therapy.Article
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QRS  duration  with  appropriate  ICD  therapy
and cardiovascular mortality. This finding is
consistent with the findings of Buxton et al.
28
where  QRS  duration  was  not  a  predictor  of
ventricular tachycardia or ventricular fibrilla-
tion resulting in ICD therapies.
Limitations 
Our data were derived from a single large
center registry. This observational study was
non-randomized and data were analyzed retro-
spectively. Thus unidentified confounders may
exist which could impact the results of this
study.
Conclusions
MetS, chronic kidney disease, left ventricu-
lar ejection fraction ≤20% and body mass index
≥28.8 kg/m
2 are significantly associated with
appropriate  ICD  therapy  in  patients  who
received ICD implantation for primary preven-
tion of sudden cardiac death. To our knowl-
edge, this is the first study to show that MetS
predicts an increased incidence of appropriate
ICD therapy and cardiovascular mortality in a
systolic  heart  failure  cohort  that  underwent
ICD  implantation  for  primary  prevention  of
sudden  cardiac  death.  Although  individual
components of MetS were not found to be inde-
pendent predictor, MetS itself was found to be
independent predictor of appropriate ICD ther-
apy. The findings of this study highlight the
importance of identifying patients with MetS
as aggressive treatment of these co-morbidi-
ties  may  decrease  appropriate  ICD  therapy
which in turn may decrease hospitalizations
and healthcare costs.
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